Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Research & Development (2016 - 2025)

Traws Pharma's Research & Development history spans 14 years, with the latest figure at $5.0 million for Q4 2025.

  • Quarterly results put Research & Development at $5.0 million for Q4 2025, up 170.99% from a year ago — trailing twelve months through Dec 2025 was $12.1 million (down 5.48% YoY), and the annual figure for FY2025 was $12.1 million, down 5.48%.
  • Research & Development for Q4 2025 was $5.0 million at Traws Pharma, up from $2.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.1 million in Q3 2024 to a low of $1.7 million in Q4 2021.
  • The 5-year median for Research & Development is $2.4 million (2023), against an average of $2.8 million.
  • The sharpest move saw Research & Development tumbled 61.51% in 2021, then skyrocketed 170.99% in 2025.
  • Year by year, Research & Development stood at $1.7 million in 2021, then surged by 116.22% to $3.8 million in 2022, then tumbled by 35.49% to $2.4 million in 2023, then fell by 23.66% to $1.9 million in 2024, then skyrocketed by 170.99% to $5.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $5.0 million, $2.3 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.